Anthony Quinn, Mb ChB, PhD

Anthony has more than two decades of biopharmaceutical industry experience. He most recently served as the president and chief executive officer at Aeglea BioTherapeutics and is currently an honorary professor of molecular and clinical medicine at the University of Dundee in the UK. Previously, Anthony served as the executive vice president, head of research and development, and chief medical officer at Synageva Biopharma until the company’s acquisition by Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he played a key role in securing the European and US approvals of Kanuma™ for lysosomal acid lipase deficiency and in building the company’s research and development organization and rare-disease drug pipeline. Prior to his role at Synageva, Anthony served as the worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, he was a professor of dermatology at Barts and The London School of Medicine. Anthony received his Bachelor of Medical Science and his MBChB from the University of Dundee and his PhD from the University of Newcastle upon Tyne. Anthony completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians of London.